Freshfields advises on listing of Giant Biogene Holding Co., Ltd on HKSE

Freshfields Bruckhaus Deringer (‘Freshfields’) has provided Hong Kong and US regulation advice to Goldman Sachs (Asia) L.L.C. and China Worldwide Money Corporation Hong Kong Securities Minimal, the joint sponsors and the underwriters in the world-wide giving and listing of shares of Large Biogene Keeping Co., Ltd on the Hong Kong Inventory Exchange (‘HKSE’). The transaction elevated proceeds of around HK$549.4m (US$70m) prior to any physical exercise of the More than-allotment Alternative. Trading in the shares commenced currently (4 November 2022).

Large Biogene Keeping Co., Ltd is a chief in the bioactive component-based mostly experienced pores and skin treatment product or service field in China. The enterprise designs, develops and manufactures qualified skin treatment merchandise with recombinant collagen as the vital bioactive ingredient. The company also develops and manufactures rare ginsenosides technological know-how-based mostly purposeful foods. The company utilises proprietary artificial biology know-how to build and manufacture several kinds of recombinant collagen and exceptional ginsenosides in-property. Bioactive ingredients present a wealth of natural beauty and well being properties such as skin repair, anti-getting older, whitening, moisturising and immunity advancement with a broad variety of apps in the beauty and well being sectors.

The Freshfields staff advising on the transaction was led by companion and head of China ECM Richard Wang, husband or wife Howie Farn and counsel Chris Fu. They had been supported by senior associate Quan Zhou, associates Xinyu Wang, Yuwei Tian, Jianhua Feng and Zhuolin Li.